The clinical human trials for COVAXIN have officially begun on Monday (July 20th) at AIIMS Delhi. After the Drug Controller General Of India (DCGI) officially gave its nod for human trials, clinical human trials for Bharat Biotech's COVAXIN have now started at AIIMS Delhi.
COVAXIN, developed by Bharat Biotech, is considered as a potential Indian vaccine against the COVID-19.COVAXIN is developed by Bharat Biotech in collaboration with the Indian Council Of Medical Research (ICMR) and the National Institute Of Virology (NIV). AIIMS Delhi has registered a number of volunteers who will undergo these human trials for COVAXIN.
All volunteers will undergo health screening before they are injected with COVAXIN. Out of 375 registered volunteers, 100 will undergo human trials for COVAXIN at AIIMS Delhi. The remaining volunteers will undergo these trails at different AIIMS across the country. Human trials for COVAXIN have already at started at AIIMS, Patna as well as other institutes.
On Monday (July 20th), human trials for COVAXIN will officially begin at AIIMS, Delhi.